Nurix Therapeutics, Inc. (NRIX)

Well-funded clinical-stage biotech with about $1.06B of cash, no debt and roughly three years of runway, but its trailing profit and single-digit multiples are artifacts of Roche's one-time $700M upfront rather than an operating turnaround: recurring collaboration revenue is small and shrinking, cash burn is roughly $325M a year, and Phase 3 plus collaborator-attrition risk keep the fundamental picture mixed.

The dominant short-term driver is a partnered-program loss: Sanofi's 2026-11-03 decision to discontinue the STAT6 degrader SAR448272 (confidence: announced), which repriced the stock roughly -28% to -35% in a session, was followed the next day by Wells Fargo cutting its target to $20 from $25, and is still being digested. The measured sentiment delta is determinately negative (baseline polarity about +0.27 over 7 scored items versus about -0.15 over 8 in the scoring window, a deterioration of roughly 0.42), a moderate red-flag cap was applied for sharp <=14-day sentiment deterioration with no offsetting in-window bullish catalyst, and the row matching this evidence is the deteriorating-sentiment/weak-sentiment row rather than the mixed row.

Broken structure, not a bullish setup. NRIX closed 2026-11-04 at 15.95, down 38.2% (-9.87) from 25.82 on 19.55M shares (~5.2x the 20-day average of 3.75M) — a single-session catalyst repricing tied to the Sanofi STAT6 program termination, not a drift. Price is below every average in the stack (SMA20 24.53, SMA50 24.73, SMA200 20.23, EMA9 24.01, EMA21 24.52, WMA9 24.27, WMA21 24.81, DEMA14 23.96, TEMA14 23.13) and below the 15.99 daily VWAP. RSI14 21.43 and Williams %R -91.14 are deeply oversold and describe a bounce-prone tape, but that is a countertrend condition: MACD has rolled over (line -0.23 vs signal 0.32, histogram -0.55) and ADX14 27.59 with price under all MAs reads as a strong DOWN trend. ATR14 1.90 = 11.9% of price with the 2026-11-04 regular range at 2.50 (17.28-14.78) — a range-expansion day that leaves the nearest structural floor at 14.78 and the year low at 11.67 as the only settled references. Score 1: bearish/broken structure with no valid long entry, and the trade is independently hard-blocked by the qualitative override (qualitativeScore 2 < 3).